|

Trastuzumab emtansine Clinical Trials

14 actively recruiting trials across 6 locations

Also known as: ADO-Trastuzumab Emtansine, Ado Trastuzumab Emtansine, Kadcyla, Kadcyla,, PRO 132365, PRO-132365, PRO132365, RO5304020, T -DM1, T-DM1, T-DM1; Kadcyla®, T-DMI, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, ado-trastuzumab emtansine

Other8 trials

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Phase 3
Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Phase 2
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
Phase 3
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
Phase 2
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Phase 2
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Phase 2

Birmingham, Alabama1 trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

University of Alabama at Birmingham Cancer Center

Phase 2

Daphne, Alabama1 trial

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Southern Cancer Center

Phase 2

Phoenix, Arizona1 trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Mayo Clinic-Arizona

Phase 1/2

Duarte, California1 trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

San Francisco, California1 trial

ATEMPT 2.0: Adjuvant T-DM1 vs TH

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 2

Houston, Texas1 trial

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.